Xenon Pharmaceuticals Inc.
NASDAQ:XENEBiotechnology
-$0.29 today
- Market cap
- $3.71B
- Beta
- 0.63
- P/E (TTM)
- -12.1
- EPS (TTM)
- -$4.39
Volume 1.30M
Average 1.16M
XENE Total Liabilities
Everything the company owes to creditors and other parties.
Xenon Pharmaceuticals Inc.NASDAQ: XENE
Total Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total liabilities rises 10.7% from a year ago
Total liabilities stood at $53.49M at the end of Q3 FY2026, up 10.7% from a year earlier and up 0.2% from the prior quarter. Over 3 fiscal years it compounded at +130.5% a year.
Context
- Total liabilities amounted to 4.5% of total assets at the end of Q3 FY2026, down 3.5 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +10.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 399.91M USD
- Year-over-year change
- +824.9%
- 4-year CAGR
- +106.5%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 399.91M | +824.9% |
| FY2024 | 2024-12-31 | 43.24M | +17.2% |
| FY2023 | 2023-12-31 | 36.88M | +12.9% |
| FY2022 | 2022-12-31 | 32.65M | +48.6% |
| FY2021 | 2021-12-31 | 21.97M | — |
Total Liabilities vs competitors
How XENE compares with its peers on the latest reported figures
- XENE's Sep 2026 total liabilities of $53.49M is the 8th highest of the 11 companies compared; the peer median is $359.83M.
- Its year-over-year change of +10.7% is the 7th highest of 11, against a peer median of +22.1%.
- Total liabilities amounts to 4.5% of total assets for XENE, versus a peer median of 27.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $7.81B | +5.5% | -1.8% | 65.1% | |
| Sep 2026 | $1.75B | +38.6% | +27.8% | 31.1% | |
| Jun 2026 | $678.14M | +19.7% | +39.4% | 89.1% | |
| Sep 2026 | $406.66M | -1.7% | +21.6% | 22.7% | |
| Jun 2026 | $396.88M | +24.6% | -21.8% | 27.8% | |
| Jun 2026 | $322.78M | +131.9% | -32.0% | 27.9% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $83.2M | +193.1% | -53.6% | 54.1% |
| Sep 2026 | $53.49M | +10.7% | +130.5% | 4.5% | |
| Sep 2026 | $52.5M | -0.7% | +15.3% | 4.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $26.09M | +60.8% | +31.9% | 5.2% |
| Dec 2025 | $6.37M | -51.5% | -4.3% | 4.8% | |
| Peer median (excluding XENE) | $359.83M | +22.1% | +6.7% | 27.8% | |
Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 175.69M | 57.24M | 148.64M | 142.71M | 199.16M |
| Short-term Investments | 376.09M | 534.85M | 489.44M | 484.19M | 349.72M |
| Net Receivables | 2.77M | 986K | 874K | 1.47M | 1.37M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 7.23M | 6.01M | 6.89M | 10.39M |
| Total Current Assets | 559.02M | 600.3M | 644.96M | 635.26M | 560.65M |
| Property, Plant & Equipment (Net) | 12.52M | 16.91M | 18.85M | 18.22M | 15.35M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 128.68M | 292.79M | 127.5M | 37.15M |
| Tax Assets | 465K | 509K | 802K | 9.67M | 361.37M |
| Other Non-current Assets | 0 | 7.75M | 7.4M | 7.5M | 7.15M |
| Total Non-current Assets | 12.99M | 153.85M | 319.84M | 162.88M | 421.02M |
| Total Assets | 572.01M | 754.15M | 964.8M | 798.14M | 981.67M |
| Account Payables | 3.82M | 8.49M | 8.6M | 5.07M | 3.89M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1.53M |
| Tax Payables | 0 | 0 | 0 | 5.69M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.94M | 5.82M | 347K | 9.93M | 21.6M |
| Total Current Liabilities | 14.32M | 22.7M | 27.27M | 35.59M | 41.79M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 348.51M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 3.2M |
| Total Non-current Liabilities | 7.65M | 9.95M | 9.6M | 7.65M | 358.12M |
| Total Liabilities | 21.97M | 32.65M | 36.88M | 43.24M | 399.91M |
| Common Stock | 783.17M | 1.07B | 1.44B | 1.46B | 1.6B |
| Retained Earnings | (357.37M) | (482.75M) | (665.14M) | (899.47M) | (1.25B) |
| Accumulated OCI | (990K) | (3M) | (77K) | (1.61M) | 335K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 550.03M | 721.5M | 927.92M | 754.9M | 581.76M |
| Total Debt | 8.26M | 10.44M | 10.9M | 9.02M | 7.94M |
| Net Debt | (167.43M) | (46.81M) | (137.74M) | (133.7M) | (191.22M) |
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
Intrinsic Alpha fair value
Locked
Current Price
$37.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.